Abstract PS5-05-09: Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib

Authors

Tomoko Sugihara
Kíria Karolline Gomes Moreira (ORCID: https://orcid.org/0000-0003-1490-6295)
Kathryn Elizabeth Hudson (ORCID: https://orcid.org/0000-0002-4974-4428)
S. Dent
Victoria Jennifer Stefaniak
M. P. Goetz
H. Soliman
A. Liepa
M. Huang

Institutions

Mayo Clinic (US)
Eli Lilly (United States) (US)
Texas Oncology (US)
University of Rochester Medical Center (US)
Moffitt Cancer Center (US)
Syneos Health (United States) (US)
Mayo Clinic in Arizona (US)
Mayo Clinic in Florida (US)

Publication Details

Journal: Clinical Cancer Research
Published: 2026-02-17
DOI: https://doi.org/10.1158/1557-3265.sabcs25-ps5-05-09
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Abstract PS5-05-09: Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib

Tomoko Sugihara, Kíria Karolline Gomes Moreira, Kathryn Elizabeth Hudson, S. Dent et al.

Feb 17, 2026

Clinical Cancer Research

Advanced Breast Cancer Therapies

article

Abstract PS5-05-09: Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib

Tomoko Sugihara, Kíria Karolline Gomes Moreira, Kathryn Elizabeth Hudson, S. Dent, Victoria Jennifer Stefaniak, M. P. Goetz, H. Soliman, A. Liepa, M. Huang

February 17, 2026article en

Abstract

No abstract available for this paper.

Clinical Cancer ResearchVol. 32(4_Supplement)

Mayo Clinic (US), Eli Lilly (United States) (US), Texas Oncology (US), University of Rochester Medical Center (US), Moffitt Cancer Center (US), Syneos Health (United States) (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US)

Good health and well-being

Openalex Percentile: Top 52%

Advanced Breast Cancer Therapies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.